Abstract:Chimeric antigen receptor T cell (CAR-T) therapy is a late-model of immune cell therapy that has been shown to be effective in refractory/recurrent B-cell leukemia and lymphoma. Compared with the traditional anti-tumor methods, CAR-T cell therapy has the advantages of higher specificity, stronger lethality and longer-lasting efficacy. Although CAR-T cells have made significant progress in the treatment of hematologic malignancies, diverse difficulties remain in the treatment of solid tumors, including immune escape due to tumor antigen heterogeneity, preventing entry or limiting the persistence of CAR-T cells by physical or cytokine barriers and along with other immunosuppressive molecule and cells in the tumor microenvironment (TME). Otherwise, the intracellular signaling of CAR also impact on CAR-T cells persistence. Appropriate modification of intracellular costimulatory molecular signal in the structure of CAR or coexpression of CAR and cytokines can provide a way to enhance CAR-T cells activity. Additionally, CAR-T cells dysfunction due to T cell exhaustion is associated with multi-factors, especially transcription factors, such as c-Jun, NR4A. Engineering CAR-T cells to coexpress or knockout transcription factors in favor of T<sub>CM</sub> memory CAR-T cells differentiation was proved to prolonged the survival of CAR-T cells. Finally, combination of CAR-T cells with oncolytic viruses, nanoparticles or immune checkpoint inhibitors provides an effective measure to improve CAR-T cells function. Here, we discuss all of these advances and challenges and review promising strategies for treating solid tumors. In particular, we also highlight that CAR-T cells have enormous potential to be used in combination with other immunotherapies.

The dilemmas and possible solutions for CAR-T cell therapy application in solid tumors

Chimeric-antigen receptor T (CAR-T) cell therapy for solid tumors: challenges and opportunities.

CAR‐T Therapy in Clinical Practice: Technical Advances and Current Challenges

Advanced Strategies of CAR-T Cell Therapy in Solid Tumors and Hematological Malignancies

A long way to the battlefront: CAR T cell therapy against solid cancers.

Current challenges and therapeutic advances of CAR-T cell therapy for solid tumors

Current Progress in CAR-T Cell Therapy for Solid Tumors

Improving the ability of CAR-T cells to hit solid tumors: Challenges and strategies

Adoptive cell therapy for solid tumors beyond CAR-T: Current challenges and emerging therapeutic advances

Influencing factors and solution strategies of chimeric antigen receptor T-cell therapy (CAR-T) cell immunotherapy

Advances and Hurdles in CAR T Cell Immune Therapy for Solid Tumors

The application of CAR-T cell therapy in hematological malignancies: advantages and challenges

Bright future or blind alley? CAR-T cell therapy for solid tumors

Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies

Challenges and strategies in relation to effective CAR-T cell immunotherapy for solid tumors

Persistence of both cords nine months post double cord blood transplantation for juvenile myelomonocytic leukaemia.

Chimeric Antigen Receptor-T Cell Therapy for Solid Tumors Require New Clinical Regimens

CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors

Emerging Approaches for Solid Tumor Treatment Using CAR-T Cell Therapy

Advances in Nanotechnology Development to Overcome Current Roadblocks in CAR-T Therapy for Solid Tumors

Chimeric Antigen Receptor (CAR)-T Cell Immunotherapy Against Thoracic Malignancies: Challenges and Opportunities